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Summary 
Haematopoietic stem cell transplantation (HSCT) remains the only cure for most haematological 
malignancies, however, the mortality rate remains high. Complications after HSCT include relapse, 
graft versus host disease (GvHD), graft rejection and infection. Over the last few years several 
groups, have demonstrated that non-HLA gene polymorphisms can be predictive of outcome after 
HSCT.  Since the glucocorticoid cortisol is pivotal in the regulation of the immune system, we decided 
to examine single nucleotide polymorphisms (SNPs) (rs6198, rs33388 and rs33389) within the 
glucocorticoid receptor (GR) and correlate with HSCT outcome. 
The training set consisted of patients (n=458) who underwent HSCT for acute leukaemia between 
1983 and 2005. In the recipients, the absence of the ACT haplotype and absence of the T allele of 
rs33388 were associated with decreased OS and the absence of the ACT haplotype, the absence of 
the T allele of rs33388 and the presence of the ATA haplotype were associated with increased risk of 
relapse. In addition, the presence of the ACT haplotype in the recipient showed a trend to be 
associated with increased risk of cGvHD. The patients in this cohort received mainly myeloablative 
conditioning (n=327). The SNPs in the glucocorticoid receptor were then investigated in a validation 
set (n=251) of HSCT patients transplanted for acute leukaemia from 2006. This cohort contained 
significantly more patients that had received reduced intensity conditioning (RIC). Some of the 
results could be validated in these patients. However, contrary to the training set, the absence of the 
haplotype ACT in the donor in this cohort was associated with increased risk of cGvHD.  Differences 
in the conditioning were shown to influence the results. 
These results are the first to associate GR SNPs with HSCT outcome and demonstrate the inherent 
problems of replicating SNP association studies in HSCT, due to different pre-transplant regimens. 
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Introduction 
Glucocorticoids such as cortisol are involved in the regulation of the immune system and 
inflammation, Rhen and Cidowski, (2005) and exert their effect through binding to the glucocorticoid 
receptor (GR), (HUGO gene nomenclature NR3C1)a transcription factor expressed in most cells. 
This receptor binds glucocorticoids in the cytoplasm and translocates them to the nucleus, where 
they influence the expression of many genes, chiefly by interfering with the binding of transcription 
factor activating protein and nuclear factor to inflammatory immune genes such as interleukin 
(IL) IL-1, IL-2, IL-3, IL-6, IL-8, and TNF and causing their down regulation, Chikanza et al (2003). 
Glucocorticoids can also induce the transcription of anti-inflammatory genes including IL-4, IL-10, IL-
13 and transforming growth factor  (TGF, Chikanza et al. (2003).   
The human glucocorticoid receptor gene contains 10 exons and has 2 main isoforms, GR- and GR- 
which are generated as a result of alternative splicing, Castro et al. (1996), Encio and Detera-
Wadleigh (1991) ) as can be seen in figure 1. Both isoforms share exons 1 to 8; for the GR-isoform, 
exons 1 to 9 are transcribed into GRmRNA, the functional GR receptor.  In the case of the GR-
isoform, exon 9a is replaced with exon 9b, resulting in GR-mRNA.GR- does not itself bind 
hormone, but is thought to have an antagonistic effect on GR- signalling by heterodimerisation 
with GR- Castro et al. (1996), Encio and Detera-Wadleigh (1991). Associations have been reported 
between GR- over expression and autoimmune disease and inflammation, Derijk et al. (2001), 
Chatzikyriakidou et al. (2009) and Van den Akker et al. (2008) but it is not clear whether this is 
actually a cause or an effect and whether this increase in GR- is enough to have an effect on the 
activity of GR-.  
The single nucleotide polymorphism (SNP) rs6198 is situated in the 3’ UTR of exon 9 of the GR 
geneand changes a consensus sequence from ATTTA to GTTTA. The ATTTA sequence is known to 
destabilise GR-mRNA, Derijk et al. (2001). The A to G substitution therefore increases the stability 
of the GR- mRNA, so this G allele is thought to be the GC resistant allele, as more GR- is available 
to bind to GR- which in turn gives less cortisol induced immunosuppression. The G allele of rs6198 
has been associated with rheumatoid arthritis (RA), Derijk et al. (2001), Chatzikyriakidou et al. 
(2009), heart disease, Van den Akker et al. (2008) and reduced nasal carriage of staphylococcus 
aureus, Van den Akker et al. (2006). More recently, a trend to an association has been found with 
the G allele of rs6198 in the patient and corticosteroid sensitive aGvHD, O’Meara et al (2015). 
In addition, SNPs in intron B of the GR gene have been shown to predispose to RA susceptibility, 
Chatzikyriakidou et al. (2009). The SNPs rs33388 (A to T substitution) and rs33389 (C to 
Tsubstitution) are in intron B and are in partial linkage disequilibrium.Carriage of the variant T allele 
of rs33388 has been positively associated with the incidence of RA (p=0.025). The AT haplotype of 
rs33388 and rs33389 has also been associated with increased glucocorticoid sensitivity, Stevens et 
al.  (2004) and it exhibits higher sensitivity to steroid treatment in children with nephritic syndrome, 
Zalewski et al. (2008). These SNPs are thought to influence gene transcription by altering consensus 
recognition sites for SR proteins, Cartegni (2002), which are serine arginine rich factors involved in 
alternative splicing of RNA. Indeed, interrogation of the splicing factor map (SFMAP) database 
suggests that rs33388 lies in consensus recognition sites for the RNA splicing factors, QK1 (rs33388) 
and SRp20, also known as SRSF3 (rs33389) and, in fact, the T allele of rs33389 is predicted to create 
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additional QK1 and SRp20 sites. In addition, rs33388 and rs33389 have roles not only in mRNA 
splicing, but also in export of mRNA from the nucleus and in protein translation, Paz et al. (2010).  
We hypothesised that SNPs in the GR gene may be associated with outcome after HSCT and 
influence acute and chronic GvHD, relapse, NRM and OS. We therefore examined the role of SNPs 
rs6198, rs33389 and rs33388 and their haplotypes on NRM, OS, relapse and the incidence of acute 
and chronic GvHD in a (training) cohort of 458 adult patient/donor pairs undergoing HSCT for acute 
leukaemia pre-2006. The role of these SNPs was then further evaluated in a second smaller 
(validation) cohort of 251 adult patient and donor pairs undergoing HSCT for acute leukaemia post 
2005. 
 
 
Materials and Methods 
Patients  
The training set consisted of 458 adult HLA matched sibling and HLA matched unrelated patient and 
donor pairs from eight European transplant centres, where 66% had received T cell replete stem cell 
grafts. They were analysed retrospectively and all of the patients had undergone HSCT for acute 
leukaemia. Transplants were conducted between November 1983 and December 2005. Relapse was 
defined as haematological relapse. The main causes of death were relapse (46%), infection (21%) 
and GvHD (18%). The validation cohort consisted of 251 adult HLA matched sibling and matched 
unrelated patient and donor pairs undergoing HSCT for acute leukaemia from January 2006 to 
January 2010 at four European centres. This cohort was also analysed retrospectively and the main 
causes of death were relapse (51.2%), GvHD (25%) and infection (14.3%). There was no overlap of 
patients between the cohorts. The samples from the patients and donors were obtained following 
informed consent and approval in accordance with EBMT guidelines and the diagnosis of GvHD was 
made following the standard criteria, Glucksberg et al. (1974). The majority of the cohort after the 
year 2000 had high-resolution tissue typing for HLA Class I A,B,C and Class II DP,DQ and DR. 
Genotyping 
DNA was prepared from archived frozen peripheral blood mononuclear cells by standard techniques, 
consisting of SDS lysis, proteinase K digestion, phenol chloroform extraction followed by ethanol 
precipitation. Genotyping for the SNPs rs6198, rs33388 and rs33389 was outsourced to Kbioscience 
(http://www.kbioscience.co.uk) using their own fluorescence based competitive PCR technology 
(KASPar). They also designed the assays for the SNPs based on the DNA sequence (50 bases) on 
either side of the SNP (Figure 1). 
Statistical Analysis  
The impact of the selected GR SNPs on survival was assessed via Kaplan Meier (log rank) tests and 
Cox regression modelling. NRM and relapse were analyzed using the method of competing risks, 
Kaplan Meier (log rank) tests and Cox regression modelling. As clinical data were categorical, 
differences between cohorts were assessed using the chi-square test with exact p values; the 
Cochran Armitage test for trend was also utilized for ordinal data. Due to the lack of time-to-event 
data for acute GvHD and chronic GvHD, statistical associations were assessed via chi-square based 
statistics and binary logistic regression modelling. Effect sizes (including hazard ratios (HRs), odds 
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ratios (ORs) and Cramér's V) together with their 95% confidence intervals (CIs) are reported.  
Univariable associations were initially evaluated; the potential confounding effect of transplant date 
was then assessed via multivariable modelling were appropriate. Significance is reported at the 5% 
level. SPSS (version 23.0) and R (version 3.1.2) were used for the computations. 
 
RESULTS  
Clinical Characteristics 
Table 1 describes patient characteristics for the two cohorts.  Transplants 2006 onwards statistically 
showed more patients were over 40 years of age, a lower proportion of female donor to male 
patient transplants, more HLA-matched unrelated donors, more reduced intensity conditioning (RIC) 
protocols, more peripheral blood stem cell transplants, less NRM, and less acute GvHD grade II-IV.  
Median follow-up times were 77 months and 19 months in the training and validation sets 
respectively. 
GR SNP Frequencies in Our Cohorts 
The occurrence of the variant alleles was comparable to that for published Caucasian allele 
frequencies for rs33388 and rs33389, but significantly different for rs6198 (all allele frequencies 
taken from the National centre for biotechnology information) as shown in Table 2. This difference 
could be because the published cohorts were actually smaller than in our study cohort, indeed as 
can be seen from table 2 for rs6198 the allele frequency in our cohort falls between the two 
published allele frequencies for Caucasians. The SNPs are in Hardy-Weinberg equilibrium (p=>0.05) 
and partial linkage disequilibrium Donn et al. (2007) and therefore, we were also able to assign each 
patient or donor a specific haplotype (i.e. ACT, ATA, ACA and GCA and the SNP order for the 
haplotype designation is rs6198, then rs33389, then rs33388). 
 
 
Training Set 
None of the GR SNP variables were found to be associated with NRM. None of the donor GR 
variables were found to be associated with OS. In the recipient, absence of the ACT haplotype 
(p=0.013, HR: 0.665, 95% CI: 0.477-0.926) and absence of the T allele of rs33388 (p=0.041, HR: 0.727, 
95% CI: 0.531-0.995) were associated with decreased OS. The Kaplan Meier survival curves for these 
SNPs are shown in Figures 2a and 2b.  
None of the donor GR SNP variables were found to be associated with relapse. The absence of the 
ACT haplotype, the presence of the haplotype ATA and the absence of the T allele of rs33388 in the 
recipient were found to be associated with increased risk of relapse (p=0.007, HR: 0.539, 95% CI: 
0.340-0.854; p=0.037, HR: 1.597, 95% CI: 1.019-2.505 and p=0.004, HR: 0.543, 95% CI: 0.354-0.831  
respectively) (Table 3). The cumulative incidence plots for relapse for the recipient GR haplotype ACT 
and ATA, and the recipient rs33388 any T allele are shown in Figure 3a 3b and 3c.   
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None of the recipient or donor GR SNP variables were found to be associated with the incidence or 
severity of acute GvHD. For cGvHD, there was an indication that carriage of the ACT haplotype in the 
recipient was associated with the incidence of chronic GvHD (p=0.075, OR: 1.833, 95% CI: 0.966-
3.478). 
Validation Set 
In this cohort, none of the GR SNP variables in either patients or donors were associated with NRM 
and OS. As in the training set, none of the donor GR SNP variables were found to be associated with 
relapse; in the recipient, in contrast to the training set, the presence of the ACA haplotype was 
associated with an increased risk of relapse (p=0.042, HR: 1.921, 95% CI: 1.003-3.678) (Table 3), the 
cumulative incidence plots are shown in Figure 3d.  
Further differences were observed between the training and validation sets with regard to acute and 
chronic GvHD.  
In contrast to the training set, the presence of the ACT haplotype in the recipient was associated 
with more severe aGvHD (grades II-IV) (p=0.009, OR: 4.073, 95% CI: 1.337-12.410) and the absence 
of the A allele of rs33388 was also associated with more severe aGvHD (p=0.037, OR: 0.420, 95% CI: 
0.190-0.929) as shown in Table 4. In addition, in the donor, the absence of the ATA haplotype and 
the absence of the T allele of rs33389 was associated with the occurrence of aGvHD (grades I-IV) 
(p=0.001, OR: 0.285, 95% CI: 0.133-0.607 for both genetic factors) as can be seen in Table 4, and 
both also showed a trend to be associated with more severe grades of aGvHD (II-IV) (p=0.055, OR: 
0.422, 95% CI: 0.184-0.965 for both genetic factors). Interestingly we found that the absence of the 
ACT haplotype in the donor was significantly associated with cGvHD (p=0.025, OR: 0.374, 95% CI: 
0.163-0.857) as shown in Table 4. 
Myeloablative and RIC Cohorts 
The two cohorts were then combined and split into two new cohorts based on the type of pre-
transplant conditioning, either RIC or myeloablative, and the analysis repeated. Again none of the 
SNP variables in the donor or recipient were associated with NRM in either of these cohorts. In the 
myeloablative cohort, the new finding was that the presence of the G allele of rs6198 in the 
recipient was associated with reduced OS (p=0.046, HR: 1.401, 95% CI: 1.001-1.964). For relapse, the 
absence of the T allele of rs33388 and the absence of the ACT haplotype in the recipient, as shown 
previously in the training cohort, was associated with increased incidence (p=0.028, HR: 0.603, 95% 
CI: 0.380-0.957, p=0.048, HR: 0.603, 95% CI: 0.362-0.999 respectively). In addition, the presence of 
the GCA haplotype and the presence of the G allele of rs6198 in the recipient were associated with 
increased risk of relapse (0.028, HR: 1.703, 95% CI: 1.047-2.768 and p=0.018, HR: 1.741, 95% CI: 
1.087-2.788 respectively). None of the SNP variables were found to be associated with aGvHD but, 
as in the trend observed in the  training set, the presence of the ACT haplotype in the recipient was 
associated with the incidence of cGvHD (p=0.046, OR: 2.012, 95% CI: 1.044-3.880). 
In the RIC cohort, the presence of the ACT haplotype and the presence of the T allele of rs33388 in 
the donor was associated with reduced OS (p=0.02, HR: 1.711, 95% CI: 1.070-2.735 and p=0.025, HR: 
1.659, 95% CI: 1.051-2.619, respectively). The absence of the G allele of rs6198 in the recipient was 
associated with increased risk of relapse (p=0.048, HR: 0.510, 95% CI: 0.256-0.999). The (double) 
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presence of the ACT haplotype, the absence of the A allele of rs33388 and the absence of the T allele 
of rs33389 in the recipient was associated with more severe aGvHD (II-IV) (p=0.021, OR: 2.598, 95% 
CI: 1.152-5.860; p=, 0.037; OR: 0.420, 95% CI: 0.190-0.931  and p=0.049, OR: 0.497, 95% CI: 0.252-
0.982, respectively) and also, in the donor, the absence of the ATA haplotype and the absence of the 
T allele of rs33389 was associated with the incidence of aGvHD (p=0.03, OR: 0.464, 95% CI: 0.241-
0.893  and p=0.024, OR: 0.474, 95% CI: 0.250-0.900, respectively). No GCR SNP associations were 
found for cGvHD in this cohort. 
As the training and validation sets have been amalgamated, it may be argued that year of transplant 
could act as a confounder in these analyses, thus the relationship between each SNP and outcome 
was again assessed via Cox regression or logistic regression (as appropriate) after controlling for time 
period (1983-2005 vs 2006-2010).  As depicted in Table 5, results are virtually unchanged after 
adjustment 
The ACT haplotype was associated with GvHD in the patient in the training, validation, myeloablative 
and RIC cohorts. In the training set and the myeloablative set it was associated with the risk of 
cGvHD (p= 0.075, OR: 1.833, 95% CI: 0.966-3.478, and p=0.046, OR: 2.012, 95% CI: 1.044-3.880, 
respectively) and in the validation and RIC set, it was significantly associated with severe aGvHD 
(grades II–IV) (p= 0.009, OR: 4.073, 95% CI: 1.337-12.410 and p=0.021, OR: 2.598, 95% CI: 1.152-
5.860, respectively). In addition, the absence of the A allele of rs33388 in both the validation and RIC 
sets was significantly associated with severe aGvHD (p=0.037, OR: 0.420, 95% CI: 0.190-0.929 and 
0.037, OR: 0.420, 95% CI: 0.190-0.931, respectively). 
Discussion 
HSCT remains the main curative therapy for patients with acute leukaemia, however the mortality 
rate remains high (40 to 60%), Bensinger and Storb (2001). In recent years several groups, including 
ourselves, have reported that non-HLA gene polymorphisms are predictive of outcome in HSCT, 
Dickinson et al. (2004). We therefore decided to investigate SNPs in the GR gene, as they have been 
shown to be involved in the inflammatory process and autoimmune disease, Balavarca et al (2015), 
Pearce et al (2016). 
We did not find any associations of the SNPs rs6198, rs33388 and r33389 with NRM in either the 
recipient or the donor in both cohorts in all analyses. In the first cohort, we found absence of the 
ACT haplotype (p=0.013, HR: 0.665, 95% CI: 0.477-0.926) and the absence of the T allele of rs33388 
(p=0.041, HR: 0.727, 95% CI: 0.531-0.995) in the recipient was associated with decreased OS. The 
ACT haplotype contains two GC resistant alleles; the C allele of rs33389 and the T allele of rs33388 so 
it could be that carriage of this inflammatory haplotype might be aiding the graft versus leukaemia 
(GVL) effect and therefore, the absence of this haplotype would result in a more immunosuppressed 
phenotype giving rise to reduced OS. Indeed, when the incidence of relapse was investigated we 
found that for the first cohort in the recipient, the absence of the haplotype ACT, the presence of 
the haplotype ATA and the absence of the T allele of rs33388 was significantly associated with 
increased incidence of relapse (p=0.007, HR: 0.539, 95% CI: 0.340-0.854;,p=0.037, HR: 1.597, 95% CI: 
1.019-2.505  and p=0.004, HR: 0.543, 95% CI: 0.354-0.831, respectively). These variants could 
therefore be influencing the GVL effect. In fact, in the second cohort, we found that the presence of 
the ACA haplotype in the recipient was associated with an increased risk of relapse (p=0.042, HR: 
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1.921, 95% CI: 1.003-3.678). This haplotype could also be detrimental to the GVL effect as, like the 
ATA haplotype, this haplotype does not contain the inflammatory T allele of rs33388. 
We found no significant associations in either the recipient or the donor for the incidence of acute 
GvHD in the first cohort. However, in the second cohort, we found that the presence of the ACT 
steroid resistant haplotype and the absence of the A allele of rs33388 in the recipient was associated 
with more severe aGvHD (grades II-IV) (p=0.009, OR: 4.073, 95% CI: 1.337-12.410 and p=0.037, OR: 
0.420, 95% CI: 0.190-0.929 respectively). We also found in the donor the absence of the ATA 
haplotype was associated with the occurrence of aGvHD (grades I-IV) (p=0.001, OR: 0.285, 95% CI: 
0.133-0.607) and showed a trend to be associated with more severe grades (II-IV). In addition, in the 
donor, the absence of the T allele of 33389 was associated with the occurrence of aGvHD (grades I-
IV) (p=0.001, OR: 0.285, 95% CI: 0.133-0.607) and showed a trend to be associated with more severe 
grades (II-IV). This could be due to the absence of the inflammatory or GC resistant T allele of 
rs33388 in the ATA haplotype. Indeed, in the first cohort, we found that the presence of the ATA 
haplotype associated with relapse (p=0.037, HR: 1.597, 95% CI: 1.019-2.505). Previous studies have 
shown the T allele of rs33388 to be associated with RA, Chatzikyriakidou et al. (2009) and the TA 
haplotype of rs33389 and rs33388 to be associated with GC sensitivity, Stevens et al.  (2004). In the 
first cohort, the presence of the GC resistant ACT haplotype in the recipient showed a trend to an 
association with cGvHD (p=0.075). Conversely, in the second cohort, we found that the absence of 
this resistant haplotype in the donor was significantly associated with the incidence of cGvHD 
(p=0.025, OR: 0.374, 95% CI: 0.163-0.857), this could be due to the biology of the transplant  
Transplant protocols have also changed dramatically over the last twenty years. In our second cohort 
the number of transplants using matched unrelated donors, transplants using peripheral blood stem 
cells as the source of stem cells and the use of RIC protocols were significantly higher. The instigation 
of RIC protocols for older patients and patients with co-morbidities, Slavin et al. (1998) could 
account for our results. Since the patients in the first cohort received chiefly myeloablative 
conditioning and more of those in the second cohort received reduced intensity conditioning, we 
decided to combine the first and second cohort, divide it into myeloablative and RIC groups and 
reanalyse.  In addition, we adjusted for transplant period (1983-2005 vs 2006-2010) and the results 
were compared with those of the unadjusted analysis (leading to virtually identical conclusions). 
For the cohort that received myeloablative conditioning (n=457) the presence of the G allele of 
rs6198 in the recipient was associated with reduced OS and increased risk of relapse (p=0.046, HR: 
1.401, 95% CI: 1.001-1.964 and p=0.018, HR: 1.741, 95% CI: 1.087-2.788 respectively). The presence 
of the GCA haplotype in the recipient was also associated with increased risk of relapse (p=0.028, 
HR: 1.703, 95% CI: 1.047-2.768). Interestingly, a recent study investigating the influence of SNPS in 
the GCR in steroid sensitive and steroid resistant aGvHD found the presence of the G allele of rs6198 
in the recipient showed a trend for association with steroid sensitive aGvHD, O’Meara et al (2015) 
indicating that in a HSCT setting the G allele is the steroid sensitive allele. The presence of the ACT 
haplotype in the recipient was associated with cGvHD (p=0.046, OR: 2.012, 95% CI: 1.044-3.880), in 
the first cohort a trend for this association was also observed. These results strengthen our 
hypothesis that the presence of SNPs which incur GC resistance induce more cGvHD and hence more 
GVL following myeloablative conditioning. There is a well-documented association between the 
occurrence of cGvHD and reduced relapse risk in HSCT, Signori et al. (2012) so this could explain our 
findings in the first patient cohort and the reanalysed cohort which received myeloablative 
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conditioning. In patients undergoing myeloablative conditioning therapy, carriage of the T allele 
rs33388 could exert its effect in the recipient in the first phase (cytokine storm) of GvHD/GvL 
induction, Nestel et al. (1992). Interestingly in both the first cohort and myeloablative conditioning 
cohort, none of the variables were significant for incidence and severity of aGvHD. 
Conversely for the RIC cohort (n=252), the presence of the T allele of rs33388 and the ACT haplotype 
in the donor were found to be associated with reduced OS, (p=0.025, HR: 1.659, 95% CI: 1.051-2.619  
and 0.02, HR: 1.711, 95% CI: 1.070-2.735 respectively) and the absence of the G allele of rs6198 in 
the recipient was associated with increased risk of relapse (p=0.048, HR: 0.510, 95% CI: 0.256-0.999). 
In this cohort we found the absence of the A allele of rs33388, the absence of the T allele of rs33389 
and the (double) presence of the ACT haplotype significantly associated with severe aGvHD (grades 
II=IV), (p=0.037, OR: 0.420, 95% CI: 0.190-0.931; p=0.049, OR: 0.497, 95% CI: 0.252-0.982 and 
p=0.021, OR: 2.598, 95% CI: 1.152-5.860, respectively). In addition, the absence of the ATA 
haplotype and the absence of the T allele of rs33389 in the donor was associated with the incidence 
of aGvHD (grades I-IV) (p=0.03, OR: 0.464, 95% CI: 0.241-0.893 and p=0.024, OR: 0.474, 95% CI: 
0.250-0.900). No associations were found for cGvHD in this cohort. Interestingly, for patients having 
RIC for HSCT, the conditioning regimen that initiates the first phase of GvHD/GvL, induction is less 
inflammatory, van der Velden et al. (2010). However, in both the second and RIC cohorts similar 
“inflammatory” genetic variables were significant for the incidence of aGvHD. The presence of the 
ACT haplotype and the absence of the A allele of rs33388 in the recipient were associated with 
severe aGvHD. In addition, in both of these cohorts, the absence of the ATA haplotype and the 
absence of the T allele of rs33389 in the donor were associated with the incidence of aGvHD.  
 
This is the first study to show that SNPs in the GR gene are associated with outcome post HSCT, and 
in addition this study also highlights the effects that different transplant regimens can have on SNP 
association studies. 
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Legend for Figure 1 Structure of the glucocorticoid gene, exons are numbered and the introns are 
labelled with letters. The positions of the SNPs that were investigated are marked with the putative 
GC resistant allele shown in red and the order of the SNPS in our haplotypes in green. 
Legend for Figure 2 Kaplan Meier survival curves for GR SNPs in the first cohort. a) Survival curves of 
the GR haplotype ACT in the recipient, log rank test p=0.013, HR: 0.665, 95% CI: 0.477-0.926. b) 
Survival curves for the T allele of GR 33388 in the recipient, log rank test p=0.041, HR: 0.727, 95% CI: 
0.531-0.995.  In all graphs the black line corresponds to absence of the haplotype/allele and the grey 
line corresponds to presence.  Crosses represent censored observations.  
Legend for Figure 3 Cumulative incidence of relapse a) For GR haplotype ACT in the first cohort, the 
black line corresponds to the absence of the ACT haplotype in the recipient and the grey line its 
presence (Gray’s test, p=0.026, cumulative incidence at 2 years for ACT present:  0.245, 95% CI: 
0.187-0.308; cumulative incidence at 2 years for ACT absent:  0.400, 95% CI: 0.284-0.512). b) For GR 
haplotype ATA in the first cohort, the black line corresponds to the absence of the ATA haplotype in 
the recipient and the grey line its presence (Gray’s test, p=0.037, cumulative incidence at 2 years for 
ATA present:  0.378, 95% CI: 0.272-0.483; cumulative incidence at 2 years for ATA absent: 0.246 
,95% CI: 0.186-0.311). c) For GR SNP rs33388 allele T in the first cohort, the black line corresponds to 
absence of T allele in the recipient and grey line corresponds to its presence (Gray’s test, p=0.011, 
cumulative incidence at 2 years for allele T present:  0.248, 95% CI: 0.191-0.309; cumulative 
incidence at 2 years for allele T absent:  0.402, 95% CI: 0.295-0.505). d) For GR haplotype ACA in the 
second cohort, the black line corresponds to the absence of the ACA haplotype in the recipient and 
the grey line its presence (Gray’s test, p=0.037, cumulative incidence at 2 years for ACA present:  
0.363, 95% CI: 0.232-0.496; cumulative incidence at 2 years for ACA absent:  0.222, 95% CI: 0.127-
0.332).  
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Table 1. Patient characteristics for the training (N=458) and validation (N=251) sets. 
  
 
Training Set Validation Set 
Effect Size 
Estimateb 
   No.     (%) No.     (%)  
       
Age of patient at transplantation 
(years) 
<20 years  26 (5.7) 2 (0.8) 0.211 
20-40 years  226 (49.3) 85 (33.9)  
>40 years  206 (45.0) 164 (65.3)  
        
Patient/donor gender combination 
Male/female  93 (20.4) 32 (12.9) 0.093 
Other  364 (79.6) 216 (87.1)  
        
Type of donor Sibling  241 (52.6) 70 (27.9) 0.238 
 HLA-matched unrelated(MUD)  217 (47.4) 181 (72.1)  
        
Haematological disease 
Acute Biphenotypic leukemia  3 (0.7) 1 (0.4) 0.048 
Acute Lymphoblastic leukemia  123 (26.9) 73 (29.1)  
Acute Myeloid leukemia  330 (72.1) 177 (70.5)  
 Acute Undifferentiated leukemia  2 (0.4) 0 (0.0)  
        
Conditioning regimen 
 
Standard myeloablative  327 (71.4) 130 (51.8) 0.196 
Reduced-Intensity (RIC)  131 (28.6) 121 (48.2)  
        
 Bone marrow  207 (47.4) 21 (10.0) 0.366 
Source of stem cells Peripheral blood  229 (52.4) 188 (89.5)  
 Both sources  1 (0.2) 1 (0.5)  
        
Stage of disease at transplantation Early  185 (45.6) 113 (47.3) 0.019 
 Intermediate  92 (22.7) 51 (21.3)  
 Late  129 (31.8) 75 (31.4)  
        
T-cell depletion T-cell depletion  154 (33.6) 91 (36.3) 0.026 
 No T-cell depletion  304 (66.4) 160 (63.7)  
        
        
Time from dianosis to transplant ≤ 12 months  330 (75.3) 175 (70.0) 0.058 
     >12 months  108 (24.7) 75 (30.0)  
        
Non Relapse Mortality Noa  324 (70.7) 201 (81.7) 0.120 
 Yesa  134 (29.3) 45 (18.3)  
        
Relapse No  319 (69.7) 175 (71.1) 0.016 
 Yes  139 (30.3) 71 (28.9)  
Acute GvHD I-IV 
 
 
 
Acute GvHD grade 0 
 
 
 
147 
 
 
(32.2) 
 
84 
 
 
(39.1) 
 
 
0.067 
 
 
Acute GvHD I-IV 
 
 
 
309 
 
 
(67.8) 
 
131 
 
 
(60.9) 
 
Acute GvHD II-IV 
 
 
 
Acute GvHD 0-I 
 
 
 
237 
 
 
(52.0) 
 
139 
 
 
(64.7) 
 
 
0.119 
 
 
Acute GvHD II-IV 
 
 
219 
 
 
(48.0) 
 
76 
 
 
(35.3) 
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Acute GvHD III-IV 
 
 
 
Acute GvHD 0-II 
 
 
 
368 
 
 
(80.7) 
 
171 
 
 
(79.5) 
 
 
0.014 
 
 
Acute GvHD III-IV 
 
 
 
88 
 
 
(19.3) 
 
44 
 
 
(20.5) 
 
Chronic GvHD  
 
 
 
No  chronic GvHD 
 
 
 
155 
 
 
(46.1) 
 
76 
 
 
(48.4) 
 
 
                 0.021 
 
Chronic GvHD 
 
 
 
181 
 
(53.9) 
 
81 
 
(51.6) 
 
     
Abbreviation : GvHD= graft versus host disease  
aNon-relapse mortality (NRM) = ‘Yes’ defined as patient dead without ever experiencing a prior relapse; non-relapse mortality (NRM) = 
‘No’ defined as patient alive without ever experiencing a prior relapse or patient has had a relapse. 
b Cramér's V with a range from 0 to 1. For this set of results, Cramér’s V statistics  of 0.1, 0.3 and 0.5 are considered small, medium and 
large effect sizes respectively (Cohen, 1988). 
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Table 2 GR SNP Frequencies in Our Cohort 
 
 Published 
Caucasian 
frequency 
Frequency in our 
population 
rs6198         
A 0.73      0.90 0.841 
G 0.27      0.10 0.159 
rs33388   
A 0.549 0.542 
T 0.451 0.458 
rs33389   
C 0.858 0.839 
T 0.142 0.161 
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Table 3  
a) Significant associations between relapse and the presence/absence of GR SNP variables in the 
training set for the recipient. 
Variable Log rank test 
(p value) 
Hazard Ratio Confidence 
Interval (95%)  
Level associated 
with Relapse 
ATA haplotype 0.037 1.597a 1.019-2.505 Presence 
ACT haplotype 0.007 0.539b 0.340-0.854 Absence 
rs33388 T allele 0.004 0.543c 0.354-0.831   Absence 
aHazard Ratio= 1.597 indicates that the hazard of relapse is 1.597 times higher when the ATA haplotype is present compared to when the 
ATA haplotype is absent; bHazard Ratio= 0.539 indicates the hazard of relapse is lower when the ACT haplotype is present compared to 
when the ACT haplotype is absent (0.539 times the hazard); cHazard Ratio= 0.543 indicates the hazard of relapse is lower when the 
rs33388 T allele is present compared to when the rs33388 T allele is absent (0.543 times the hazard) 
b) Significant associations between relapse and the presence of the ACA haplotype in the recipient 
GCR in the validation set.  
Variable Log rank test 
(p value) 
Hazard Ratioa Confidence 
Interval (95%) 
Level associated 
with Relapse 
ACA haplotype 0.042 1.921 1.003-3.678 Presence 
aHazard Ratio= 1.92 indicates that the hazard of relapse is 1.92 times higher when the ACA haplotype is present compared to when the 
ACA haplotype is absent 
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Table 4 Associations between aGvHD and cGvHD  and presence/absence of GR SNP variables in the  
validation cohort 
 
aInterpretation: Odds Ratio= 4.073 indicates that the odds of aGvHD II-IV is 4.073 times higher when the ACT haplotype is present 
compared to when the ACT haplotype is absent; Odds Ratio= 0.420 indicates the odds of aGvHD II-IV is lower when the rs333888 A allele is 
present compared to when the r333888 A allele is absent (0.420 times the odds) etc. 
bAssociation with aGvHD grades II-IV.  
cAssociation with aGvHD grades I-IV,  
dAssociation with cGvHD.  
Abbreviation: aGvHD=  acute graft vs host disease, cGvHD= chronic graft versus host disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Chi-
square 
test 
(p-value) 
Odds Ratioa Confidence 
Interval (95%) 
Level associated 
with GvHD 
Recipient ACT haplotypeb 0.009 4.073 1.337-12.410 Presence 
Recipient rs333888 A alleleb 0.037 0.420 0.190-0.929 Absence 
Donor ATA haplotypec 0.001 0.285 0.133-0.607 Absence 
Donor rs333889 T allelec 0.001 0.285 0.133-0.607 Absence 
Donor ACT haplotyped 0.025 0.374 0.163-0.857 Absence 
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Table 5 Associations between aGvHD and cGvHD and presence/absence of GR SNP variables – 
adjusted and non-adjusted analysis comparison 
 Unadjusted association with outcome Adjusted  association with outcomea 
 Odds Ratio/Hazard ratio (95% CI) Odds Ratio/Hazard ratio (95% CI) 
Myeloablative   
Overall Survival   
Recipient rs6198 G allele 1.401 (1.001-1.964) 1.402 (1.001-1.966) 
Relapse   
Recipient rs33388  T allele 0.603 (0.380-0.957) 0.608 (0.382-0.968) 
Recipient ACT haplotype 0.603 (0.362-0.999) 0.608 (0.364-0.999) 
Recipient GCA haplotype 1.703 (1.047-2.768) 1.709 (1.051-2.778) 
Recipient rs6198  G allele 1.741 (1.087-2.788) 1.746 (1.091-2.797) 
cGvHD   
Recipient ACT haplotype 2.012 (1.044-3.880) 1.998 (1.031-3.871) 
   
Reduced Intensity 
Conditioning 
  
Overall Survival   
Donor rs33388  T allele 1.659 (1.051-2.619) 1.673 (1.058-2.648) 
Donor ACT haplotype 1.711 (1.070-2.735) 1.713 (1.070-2.742) 
Relapse   
Recipient rs6198  G allele 0.510 (0.256-0.999) 0.510 (0.256-0.999) 
aGvHD II-IV   
Recipient ACT ACT 
haplotype 
2.598 (1.152-5.860) 2.524 (1.104-5.771) 
Recipient rs33388  A allele 0.420 (0.190-0.931)   0.434(0.193-0.975)   
Recipient rs33389  T allele 0.497 (0.252-0.982) 0.466 (0.232-0.935) 
aGvHD I-IV   
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aadjusted for time period (1983-2005 vs 2006-2010) 
Abbreviation: aGvHD=  acute graft vs host disease, cGvHD= chronic graft versus host disease 
 
 
 
 
 
 
 
Donor ATA haplotype 0.464 (0.241-0.893) 0.462 (0.240-0.891) 
Donor rs33389  T allele 0.474 (0.250-0.900) 0.473 (0.249-0.899) 
